Widens the Availability of its CBD ProductsHicksville, NY - (NewMediaWire) - March 11, 2019 - Canbiola, Inc. (OTCQB: CANB) (“Canbiola” or the “Company”), a developer, manufacturer and seller of a variety of Cannabidiol (Hemp) based products such as oils, creams, moisturizers, chews, isolate, gel caps, and concentrate, announced today that it is now registered and active in the U.S. government GSA’s System for Award Management (SAM) and Department of Defense (DOD).The System for Award Management (SAM) is an official website of the U.S. government. There is no cost to use SAM. GSA’s Office of Government-wide Policy is consolidating federal procurement and award systems into 1 new system—the System for Award Management (SAM). SAM is streamlining processes, improving data quality by eliminating the need to enter the same data multiple times, and consolidating hosting to save taxpayer money.The registration number for Canbiola, Inc. is 789110553 / 5C7D3 and is now active in the U.S. federal government's System for Award Management (SAM/DOD).For additional information, please visit:https://www.sam.gov/SAM/https://www.acq.osd.mil/dpap/pdi/eb/system_for_award_management.htmlCanbiola Chief Executive Officer Marco Alfonsi, commented, “Attaining SAM and DOD registration is quite an accomplishment and something our team at Canbiola had been working on for some time. We are proud to now be active in the system, which enables our products to be more widely available to those who seek CBD solutions. We look forward to being an active participant in the U.S. government program.”About Canbiola, Inc.Canbiola, Inc. (OTCQB: CANB) is a developer, manufacturer and seller of a variety of Cannabidiol (Hemp) based products such as oils, creams, moisturizers, chews,, isolate, gel caps, and concentrates. Canbiola has developed its own line of proprietary products as well as seeking synergistic value through acquisitions in the CBD and the medical cannabis industry. Cannabis is currently federally illegal and has legalized for medical purposes in some form in a limited number of states, but pure CBD products are legal in all 50 states. Hemp CBD is the non-psychoactive component (No THC) used for treatment of pain, inflammation, and wellness programs. For more information about Canbiola, Inc., please visit: https://canbiola.com.Additionally, Canbiola’s wholly owned subsidiary Pure Health Products, based in Lacey, WA, is its prime development laboratory and production facility. Canbiola’s Duramed division has recently rolled out a durable medical device via its Doctor network to treat patients with injuries via application of an in-home ultrasound sustained acoustic device for pain and inflammation reduction.Forward-Looking StatementsForward-looking statements and risks and uncertainties discussed in this letter contain forward-looking statements. The words "anticipate," "believe," "estimate," "may," "intend," "expect," and similar expressions identify such forward-looking statements. Expected, actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. The matters discussed herein should not be construed in any way, shape or manner of our future financial condition or stock price.Follow Canbiola on: Twitter @CanbiolaHealthInstagram @canbiola.inc or @canbiola_cbd or @canbiola_medical_cbdFollow us on Twitter and FacebookInvestors and Media: IR@canbiola.com (516) 595-9544 Hayden IR hart@haydenir.com (917) 658-7878

Shares of eHealth (EHTH) is expected to continue the bull run backed by solid fundamentals and initiatives to ramp up growth.

Essen, Germany - (NewMediaWire) - March 11, 2019 - Huawei’s 5G outdoor customer-premises equipment (CPE) wins Red Dot Award: Product Design 2019 recently. Huawei's 5G CPE 2.0 won the award for its cutting-edge design concept and unparalleled innovation that is breaking new ground in the development of 5G. Product Design of Red Dot Award is considered as the world's most renowned product design award and is an established symbol of excellent design worldwideHuawei’s 5G outdoor CPE2.0 is designed by Huawei's CPE team in China and the Huawei design team in Munich, Germany, based on the concept of “Ridge”, which symbolize Huawei's dedication to providing optimal 5G experience for users, and Huawei's spirit of continuous self-challenge. The CPE 2.0's unique Ridge design also integrates indoor and outdoor devices, users, and the environment. The top of the indoor unit tilts forwards and faces users, representing its user-friendliness. The outdoor unit faces the base station and presents a neat and elegant appearance to users.The 5G era will see an explosion of data transmission, with a qualitative leap in communication speed and experience requirements. The outdoor design of Huawei's 5G CPE 2.0 enables it to provide stronger signals. The CPE 2.0's high signal strength and computing power allows it to provide data speeds higher than 3.5 Gbit/s, which is dozens of times higher than current home broadband speeds.Huawei's 5G CPE 2.0 is also fully compatible with 4G networks and frequency bands. This allows it to simply and seamlessly replace 4G outdoor CPEs in an extremely simplified manner, with no user installation and maintenance.2019 is the first year for large-scale commercial use of 5G. 5G wireless to the x (WTTx) has been widely recognized as a major 5G application scenario.Huawei's CPE 2.0 was designed with simplified installation and optimal experience in mind. It supports all mainstream 5G frequency bands and meets the requirements for large-scale commercial use of 5G. The CPE 2.0 promotes 5G development and marks a new milestone in the search for ever better means of communication."Huawei started investing in CPE research in 2016—two years before the 3GPP Release 15 specifications that established the standards for 5G New Radio (NR) were frozen," said Yu Jun, Huawei's 5G CPE product director. "Huawei's early investment in 5G CPE research reflects our sense of responsibility for driving forward the development of the entire 5G industry.""Winning the Red Dot Award boosts Huawei's confidence in our mission to continuously develop better products and to bring the best 5G experience to every household," Yu said. The 5G era is here. Huawei is committed to redoubling its efforts and investments in 5G end-to-end product research and development, so as to provide faster and better 5G services to all households and societies.John Leung John.leung@wmglobal.com

Dilution Has Been SuspendedNewport Beach, CA - (NewMediaWire) - March 11, 2019 - M Line Holdings, Inc. (OTC Pink: MLHC; "M Line" or the “Company”) announces that it has negotiated a suspension of dilution with its debt holders. This would not have been possible some weeks ago and we are very pleased that the lenders have recognized that we need to improve shareholder value.We have achieved a great deal over the last 8 months and to those parties not familiar with our growth I have summed it up below:August, 2018We acquired 55% of The Caravel Group, our beverage branding and distribution Company55% of Best Choice Food and Beverage our food and beverage Distribution Company located in Florida and another 20% in September.September, 2018We acquired Best Choice Nuts, Candy and Specialties, Inc., another beverage and food distributor in Florida, and began the process of merging the two Best Choices into one operation.October, 2018We acquired 60% of American Asset Holdings, Inc. the company that builds our “off the grid” growing pods used to grow cannabis and vegetables.We acquired Dimension Beverages, LLC, which owned the Torque® brand of energy drinks. We have since transferred the management of this brand to the Caravel GroupWe announced that we were entering into a joint venture to market the “Rise” brand of CBD products. This is the ONLY transaction we have not closed yet however we expect to do so very shortly.January, 2019We announced that we have acquired the rights to the Larry Caputo brand of imported wines. The first shipments from Italy will be arriving in March 2019 a little behind our original schedule.February, 2019We acquired three operating restaurants/bars, an event center, and 38.5 acres of land in Arizona.March, 2019As mentioned in previous releases, we have major news to be released as soon as possible.Tony Anish, CEO of M Line, commented: “This astonishing growth has not yet been reflected in Shareholder Value, however with Revenues and EBITDA continuing to improve we know this will change. I want to thank our debt lenders for working with us to help improve Shareholder Value.” Tony continued: “To our shareholders, I want to state again, we have NO intention of reversing our stock, but we do intend to be able to start a share buy-back program very soon.”About M Line Holdings, Inc.M Line is a Holding Company. It controls subsidiaries involved in the Beverage Branding and Distribution industry that includes our branded drinks. In addition, M Line controls two subsidiaries in Florida in the Food and Beverage distribution business and M Line has now expanded into the Cannabis Industry with the acquisition of our C-Pod manufacturing business. M Line owns three restaurants and an event center in Arizona and land for development. M Line will continue with its business financing activities while looking for other opportunities in the Beverage, Distribution, hospitality and Cannabis industries as well as other prospects that make sense to management.Safe Harbor and Informational StatementThis press release may contain forward-looking information within the meaning of Section 21E of the Security Exchange Act of 1934, as amended (the Exchange Act), including all statements that are not statement of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial conditions or results of operations; (iii): the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends.The words "may", "would", "will", "expect", "estimate", "anticipate", "believe", "intend", and similar expressions and variations thereof are intend to identify forward-looking statements. Investors are cautioned that any such forward-looking statement is not a guarantee of future of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control, and that actual results may differ materially ...

Atlanta, GA - (NewMediaWire) - March 11, 2019 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines and immunotherapies using its novel viral vector platform technology, today provided an update on its progress and development programs.David Dodd, GeoVax President and CEO, commented, “We continue to advance GeoVax’s development programs on multiple fronts with an expanding list of world-class government, academic and corporate collaborators, as further described in this update. I am pleased with what the GeoVax team has accomplished during 2018 and so far in 2019, but I also recognize that our constrained capital resources continue to limit our ability to meaningfully advance our products as rapidly as we would like. Going forward, we will continue to evaluate options to secure the capital needed to proceed with our business plan, especially to advance further programs into human clinical testing. We view this as critical to our overall corporate development and enhancement of shareholder value. I remain highly optimistic about the future of our company and I look forward to sharing additional news in the coming months. All of us at GeoVax wish to thank our shareholders for their continued support as GeoVax progresses toward a status of having multiple clinical programs underway, addressing various infectious diseases and cancer indications, having a capital structure that supports continued execution of our strategy and business plan.”A few highlights from 2018 and early 2019 include:Immuno-oncology - A Promising and Expanding Program. We began 2018 with a single program in this area (tumor-associated MUC1 vaccines) supported by two collaborations (University of Pittsburgh and ViaMune) and that work is continuing to expand and advance. During 2018, we added four more collaborations to expand our footprint in this space -- with Vaxeal Holding SA (Cyclin B1 tumor-associated antigen), Emory University (HPV-related head and neck cancers), Virometix AG (also for HPV-related cancers), and Leidos, Inc. (multiple potential cancer targets). We believe immuno-oncology to be important for the future of GeoVax and we intend to vigorously pursue development of these programs. Raising sufficient capital will be key to rapidly advancing in this area.Defense Department Grant - Our First Entrée into the U.S. Government Biodefense System. In September the U.S. Department of Defense (DoD) awarded us a $2.4 million grant to support our Lassa Fever vaccine program. The DoD will also fund testing of our vaccine by U.S. Army scientists at USAMRIID under a separate sub-award. This grant represented an important advance by GeoVax into the critical area of biodefense which we believe represents a significant growth area for the application of our technology and expertise.HIV “Cure” Program - New, Exciting Possibilities. Our collaboration with American Gene Technologies International, Inc. (AGT), for use of our vaccine in combination with AGT’s gene therapy for development of a functional cure for HIV, is on track to enter a Phase 1 trial sponsored by AGT. AGT anticipates starting the trial during the second half of 2019. We are also in discussions with two other consortiums for the possible use of our vaccine in similar efforts toward developing a cure for HIV infection. We expect that one or both of these studies may begin in late 2019 or early 2020.HIV “Prevention” Program - Continued Progress with NIH Support. In October, positive results from HVTN 114, a phase 1 trial of our preventive HIV vaccine, were presented at the HIVR4P conference in Madrid. The clinical trial program for our preventive HIV vaccine continues to be supported by the NIH and the HIV Vaccine Trials Network (HVTN), with the next study (HVTN 132) expected to commence later this year. Furthermore, during President Trump’s recent State of the Union address, he committed to pursuing the elimination of HIV within the next decade. We view our preventive vaccine developments as being critical and core to this initiative.NIH Support for ...